SUNNOVO 阳光诺和 2027 北京阳光诺和药物研究股份有限公司 Beijing Sun-Novo Pharmaceutical Research Co.,Ltd 股票简称:阳光诺和 股票代码:688621 HB SC F T HRSCHOlors b为领先的医药研发专家 2022年实现营业收入 实现归母净利润 每股收益 67,660.64 万元 累计服务客户数 650+ 家 新增订单 存量在手订单 11.02 亿元 2022年 UUU 研发成果一览 1.95 元/股 15,594.97 万元 19.94亿元 8项 新药项目通过NMPA批准进入临床试验 60项 药品申报上市注册受理 24项 一致性评价注册受理 取得 26项 药品生产注册批件 通过 15项 一致性评价 获批 3项 原料药 FFF FIFTER ROFF - HE 研发投入 8,968.57 万元 研发投入占营收比例 13.26% 研发技术团队 951 人 研发人员占比 84.46% 实验室总面积 ~ 3.60 万平方米 实验室投产比例 83.06% ▲ 实验室展示 2022 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2023-020 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 03 月 23 日上午 10:00-11:00 会议召开时间：2023 年 03 月 23 日(星期四)上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 16 日(星期四)至 03 月 22 日(星期三)16:00 前登录 上证路演中心网站首页点击 " 提问预征集 " 栏目或通过公司邮箱 ir@sun-novo.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 北京阳光诺和药物研究股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在 ...

Financial Performance - In 2022, the company achieved operating revenue of 676.61 million yuan and a net profit attributable to shareholders of 155.95 million yuan, with earnings per share of 1.95 yuan[4]. - The company reported a total revenue of RMB 500 million for the fiscal year 2022, representing a year-over-year increase of 25%[22]. - The company achieved operating revenue of 676.64 million yuan in 2022, representing a year-on-year growth of 37.06%[44]. - Net profit attributable to shareholders reached CNY 155.95 million, up 47.59% compared to the previous year[32]. - The net profit after deducting non-recurring gains and losses was CNY 141.63 million, reflecting a growth of 38.69% year-on-year[32]. - The net cash flow from operating activities increased by 17.80% to CNY 103.96 million[32]. - The company's total assets at the end of 2022 were CNY 1,463.09 million, a 17.74% increase from the previous year[33]. - The net assets attributable to shareholders grew by 17.68% to CNY 896.70 million[33]. - The company reported a total revenue of 4,391,429.00, with a net profit of 534,178.16, indicating a strong financial performance[93]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the fiscal year, representing a 20% growth compared to the previous year[182]. Research and Development - Research and development investment totaled 89.69 million yuan, accounting for 13.26% of revenue, with a research team of 951 personnel, representing 84.46% of the workforce[7]. - The proportion of R&D investment to operating revenue increased by 3.62 percentage points to 13.26%[31]. - The company has invested RMB 50 million in new technology for drug formulation, aiming to improve production efficiency by 25%[22]. - The company reported a total R&D expenditure of ¥89,685,673.07, an increase of 88.51% compared to the previous year, driven by investments in innovative drugs and improved generic drugs[72]. - The company is focusing on the development of innovative drugs, particularly in the areas of peptide and small nucleic acid drugs, with all research projects being self-initiated[49]. - The company is enhancing its capabilities in innovative drug services, focusing on peptide-based drugs and advanced drug design technologies[2]. - The company is actively pursuing new technology development to enhance the efficiency of its manufacturing processes[92]. Market Expansion and Strategy - The company plans to distribute a cash dividend of 6.00 yuan per 10 shares, totaling 48 million yuan, which represents 30.78% of the net profit attributable to shareholders[11]. - The company is expanding its market presence in Southeast Asia, targeting a 20% market share by the end of 2024[22]. - The company is exploring market expansion opportunities in the field of chemical generic drugs, particularly in the treatment of hypertension[84]. - The company is actively pursuing the registration of multiple new products, with several in the trial phase, indicating ongoing innovation[96]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[182]. - The company aims to expand its business by acquiring 100% equity of Langyan Life Science, which specializes in high-end chemical drug formulation and raw material production[165]. Product Development and Pipeline - Eight new drug projects received NMPA approval for clinical trials, with 60 drug applications accepted for market registration and 24 for consistency evaluation[5]. - The company has received approval for 26 drug production registration certificates and 15 consistency evaluations[5]. - New product development includes the launch of two innovative drugs, expected to enter the market in Q3 2023, with projected sales of RMB 100 million each in the first year[22]. - Clinical trials for three new drugs are currently underway, with expected completion by Q4 2023[22]. - The company has successfully initiated 8 new drug projects that have received NMPA approval for clinical trials, along with 60 drug registration applications accepted[70]. Operational Efficiency - The overall operational cost has been reduced by 10% due to improved supply chain management[22]. - The average output per employee reached CNY 600,900, an increase of CNY 35,400 compared to the previous year[32]. - The company has implemented a new marketing strategy focusing on digital channels, aiming to increase customer engagement by 40%[22]. - The company has established a comprehensive "preclinical + clinical" drug development service model, improving the probability of successful drug development[100]. Risk Management - The company has outlined potential risks in its annual report, emphasizing the importance of risk awareness for investors[9]. - The company faces risks related to technological upgrades and potential drug development failures, which could impact future profitability[105]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring clear responsibilities and effective operation among its governing bodies[172]. - The company maintained a stable management team with no significant changes in shareholding for key executives during the reporting period[179]. - The company’s board of directors is responsible for submitting the remuneration plans to the shareholders' meeting for approval[193]. Human Resources - The company employs 1,126 staff, with 951 in R&D, representing 84.46% of total employees[60]. - Total compensation for R&D personnel reached 140,189,477.04 RMB, with an average salary of 168,294.69 RMB, compared to 154,338.83 RMB in the previous year[99]. - The average age of R&D personnel shows a youthful demographic, with 657 individuals under 30 years old, which may contribute to innovative approaches[99]. Financial Management - The company reported a significant decrease in financing cash flow, down 95.39% to ¥26,219,083.13, compared to the previous year[133]. - Accounts receivable increased by 85.19% to CNY 202,697,666.92, driven by revenue growth, although collection was slower due to the pandemic[136]. - The company’s financial assets decreased by 91.68% to CNY 13,107,081.60, primarily due to the maturity of purchased financial products[136].

证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 投资者关系活动记录表 （2022 年 5 月） | --- | --- | --- | |-----------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n 媒体采访 \n□新闻发布会 □路演活动 \n 现场参观 \n□其他（电话会议） | 分析师会议 \n 业绩说明会 | | 参与单位名称 同花顺 | | | | 时间 2022 | 年 5 月 31 日 | | | 参会方式 | 媒体采访录制 | | | 上市公司接待人 员姓名 | 董事、总经理：刘宇晶先生 | | | | 1. | 公司未来的核心业务增长点是什么？ | | | | 回复："仿创结合，一站式服务"是公司发展的主 | | | | 要方向，基于这个 ...

SUNNOVO 阳光诺和 阳光诺和 2022三季度报告 北京阳光诺和药物研究股份有限公司 股票代码：688621 2022 年三季度报告 单位：元 币种：人民币 证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 2022 年三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性依法承担 法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|------ ...

1 / 167 2022 年半年度报告 北京阳光诺和药物研究股份有限公司 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性 承担法律责任。 二、重大风险提示 本公司已在本半年度报告中详细阐述在生产经营过程中可能面临的相关风险，详情请查阅本 报告第三节、五、"风险因素"部分的相关内容。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、前瞻性陈述的风险声明 √适用 □不适用 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质性承诺，敬请投资者注意投 资风险。 九、是否存在被控股股东及其关联方非经营性占用资金情况 否 十、是否存在违反规定决策程序对外提供担保的情况？ 否 十一、是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 2022 年半年度报告 第一节 释义 在本报告书中，除非文义另有所指，下列词语具有如下含义： | 常用词语释义 | | | | ...

北京阳光诺和药物研究股份有限公司 2022 年第一季度报告 单位：元 币种：人民币 1 / 14 证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期比上年 | --- | --- | --- | |-----------------------------------------------|----------------|-----------------------| | 项目 | 本报告期 | 同期增减变动幅 度 (%) ...

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the fiscal year 2021, representing a year-over-year growth of 25%[21]. - The company achieved operating revenue of RMB 493.65 million in 2021, a year-on-year increase of 42.12%[30]. - Net profit attributable to shareholders reached RMB 105.66 million, up 45.81% compared to the previous year[30]. - The net cash flow from operating activities was RMB 88.25 million, reflecting a growth of 40.09% year-on-year[30]. - The company signed new orders worth RMB 929 million in 2021, representing a 76.42% increase from the previous year[30]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[21]. - The net profit margin was 22.04%, an increase of 0.69 percentage points compared to the previous year[46]. - The comprehensive gross margin for the reporting period was 53.41%, indicating a relatively high level[141]. Research and Development - The R&D investment for new products and technologies increased by 15%, totaling RMB 300 million in 2021[21]. - The company invested 9.64% of its operating revenue in R&D, slightly down from 9.84% in the previous year[30]. - The average output value per R&D personnel reached 565,500 RMB, an increase of 53,200 RMB compared to the previous year[46]. - The company has initiated 5 new drug IND applications, with 3 already obtaining clinical approval[47]. - The company has established advanced analysis platforms, including mass spectrometry and immunoassay platforms, to support pharmacokinetics and biomarker studies[71]. - The company is focusing on the development of innovative drugs, particularly peptide and small nucleic acid drugs, with all research projects being self-initiated[52]. - The company has a total of 873 employees, with 716 in R&D, accounting for 82.02% of the total workforce[48]. Market Expansion and Strategy - The company announced plans for market expansion into Southeast Asia, targeting a 10% market share within the next two years[21]. - A strategic acquisition of a local competitor was completed, valued at RMB 500 million, expected to enhance market presence and operational capabilities[21]. - The company is actively pursuing market expansion strategies and exploring potential mergers and acquisitions to enhance its product portfolio[39]. - The company collaborates with early-stage innovative drug R&D teams to enhance service offerings in pharmacokinetics and biomarker detection[52]. Corporate Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[11]. - The company does not have any special arrangements for corporate governance[8]. - The audit report issued by Da Hua Certified Public Accountants is a standard unqualified opinion[6]. Risks and Challenges - The company faces risks related to the rapid technological updates in the CRO industry, which may impact its future profitability and sustainable development[137]. - There is a risk of core technical talent loss and leakage, which could adversely affect the company's competitiveness and profitability[138]. - The long project cycles in the pharmaceutical research industry, typically ranging from 3 to 5 years, pose execution risks that may affect expected revenues[141]. - Future declines in pharmaceutical R&D investments due to macroeconomic conditions could negatively impact the demand for CRO services and the company's operational performance[145]. Product Development and Innovation - The company is focusing on strict quality control measures in the production of complex formulations, such as the combination of Valsartan and Amlodipine, due to the instability of raw materials[2]. - The company is actively pursuing new product development, with ongoing clinical trials for several formulations, including the Indobufen and the dual vinegar capsule[2]. - The company has developed a drug delivery system for small nucleic acid drugs, entering the small nucleic acid drug development field[71]. - The company has completed the technology transfer for multiple products, including the Indobufen and the dual vinegar capsule, indicating ongoing product development and regulatory compliance[2]. Financial Position and Assets - The company’s accounts receivable increased by 112.78% to CNY 109,454,952.74, driven by rapid revenue growth[183]. - The company’s total assets included CNY 157,600,000.00 in trading financial assets, primarily from purchasing cash management products[183]. - The cash and cash equivalents at the end of the period reached CNY 490,251,185.19, a 348.52% increase from CNY 109,305,218.92[183]. - Short-term borrowings surged to ¥138,005,000.00, a 487.26% increase from ¥23,500,000.00, mainly due to increased bank loans[189].

2021 年第三季度报告 证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|---------------------------------------|----------------|------------------------------------------------------ ...

2021 年第三季度报告 证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|---------------------------------------|----------------|--------------------------------------- ...